Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATES
WINNING BID FOR THE MEDICAL PROJECT OF TIANJIN BEICHEN HOSPITAL

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Jiangxi Rimag Group Co., Ltd. (the "**Company**", together with its subsidiaries collectively referred to as the "**Group**") on a voluntary basis.

The Board is pleased to announce that Tianjin Rimag Yingrun Medical Imaging Diagnostics Co., Ltd. (天津一脈盈潤醫學影像診斷有限公司), a subsidiary of the Company, being the leading party of the consortium, won the bid for the "Medical Project of Tianjin Beichen Hospital" ("天津市北辰醫院醫療項目") (Tendering No.: YTKX2025-B-070) on October 24, 2025, and obtained the bid winning notice. It is expected that the Group, together with other members of the consortium will duly execute a project cooperation agreement with Tianjin Beichen Hospital (天津市北辰醫院) in the near future.

The project represents the first government-collaborative regional healthcare resource integration project implemented by the Group in the Tianjin region, with annual revenue estimated to reach tens of million RMB, signifying substantial progress in the Group's strategy of "focusing on key regions with nationwide reach". The project will centre on five key modules including the Regional Imaging Sharing Centre, the Smart Integrated Laboratory, the Digital Pathology Centre, the Health Management Centre, and the Nuclear Medicine Centre, establish a regional digital and intelligent healthcare sharing platform, and enhance the synergy of medical resources and service efficiency.

Established in October 1963, Tianjin Beichen Hospital (天津市北辰醫院) is a Grade 3A integrated hospital offering medical treatment, prevention, healthcare and rehabilitation, boasting multiple key specialties designated by Beichen district and having a solid disciplinary foundation and significant regional influence. The successful bid for such project not only demonstrates the recognition gained from government bodies and high-end medical institutions in respect of the Group's comprehensive service capabilities across the entire ecosystem of medical imaging, pathological diagnosis and health management but also signifies that the Group will export its standardised operational management system and technical expertise to assist hospitals in achieving resource optimisation, efficiency enhancement and service closure through innovative collaborative models.

The Board considers that the project, being the Group's inaugural fully integrated initiative encompassing imaging, diagnostics, pathology, nuclear medicine and health management, not only demonstrates the Group's capacity for regional healthcare resource coordination and intelligent operations, but also lays a solid foundation for the subsequent rollout of similar projects across the Beijing-Tianjin-Hebei region. The implementation of the project will further strengthen the Group's market presence in northern China, laying a solid foundation for the expansion of similar projects in the future, and holding significant strategic value for the Group's long-term development.

This announcement is issued voluntarily to provide an update on the Group's latest business developments. The subsequent implementation of this project may be subject to uncertainties including policy adjustments, changes in market conditions, and execution progress falling short of expectations. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 24, 2025

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.